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Introduction: MicroRNAs (miRNAs) are an abundant class of small 
non–protein-coding RNAs that function as negative gene regula-
tors. Recent evidence indicates that altered miRNA expression plays 
an important role in the initiation and progression of lung cancer. 
Single nucleotide polymorphisms (SNPs) in pre-miRNAs could alter 
miRNAs processing, or expression, and hence, could influence the 
prognosis of lung cancer. To test this hypothesis, we evaluated the 
effects of four SNPs in pre-miRNAs (pre-miR-146a rs2910164, pre-
miR-149 rs2292832, pre-miR-196a rs11614913, and pre-miR-499 
rs3746444) on the survival outcomes of patients with early-stage 
non–small-cell lung cancer (NSCLC).
Methods: Three hundred sixty-three patients with surgically resected 
NSCLC were enrolled. The four SNPs were genotyped using a poly-
merase chain reaction-restriction fragment length polymorphism 
assay. The genotype associations with overall survival (OS) and dis-
ease-free survival (DFS) were analyzed.
Results: Of the four SNPs examined, the pre-miR-149 rs2292832T>C 
and pre-miR-196a rs11614913C>T were found to be significantly 
associated with OS and DFS. The rs2292832 TC or CC genotype 
exhibited a significantly better OS and DFS compared with the 
rs2292832 TT genotype (adjusted hazard ratio [aHR] for OS, 0.66; 
95% confidence interval [CI], 0.47–0.92; p = 0.01 and aHR for 
DFS, 0.64; 95% CI, 0.48–0.87; p = 0.004). For the pre-miR-196a 
rs11614913C>T, patients with the CT or TT genotype had a signifi-
cantly better OS and DFS than those with the CC genotype (aHR 
for OS, 0.70; 95% CI, 0.49–0.99; p = 0.05 and aHR for DFS, 0.66; 
95% CI, 0.48–0.90; p = 0.01). When the two SNPs were combined, 
OS and DFS improved in a dose-dependent manner as the number of 
good genotypes increased (p = 0.002 and 0.0001, respectively).
Conclusions: These results suggest that miR-149 and miR-196a may 
be involved in the pathogenesis of NSCLC, and that rs2292832 and 
rs11614913 can be used as prognostic markers for patients with sur-
gically resected early-stage NSCLC.
Key Words: MicroRNA, Polymorphism, Non–small-cell lung can-
cer, Survival.
(J Thorac Oncol. 2013;8: 703-710)
Non–small-cell lung cancer (NSCLC) accounts for 80% to 85% of all cases of lung cancer and is the leading cause 
of cancer-related death in most countries, with less than 15% 
of patients surviving beyond 5 years.1,2 The relapse rate among 
patients with early-stage NSCLC is 40% within 5 years after 
potentially curative surgical resection.3 Although the tumor, 
node, and metastasis staging system has been the standard 
for determining the prognosis of operable NSCLC, there are 
marked differences in recurrence and survival within the same 
staging group, indicating the inadequacy of the tumor, node, 
and metastasis staging system to account fully for this hetero-
geneity. Therefore, it is necessary to develop biomarkers that 
reliably identify those at high risk of relapse after surgery to 
potentially improve survival through modified adjuvant therapy.
MicroRNAs (miRNAs) are non-coding RNAs with a 
length of approximately 22 nucleotides. MiRNAs are involved 
in crucial biological processes, including development, differ-
entiation, apoptosis, and proliferation, through imperfect pair-
ing with target mRNAs of protein coding genes, and through 
the transcriptional or posttranscriptional regulation of their 
expression.4,5 Several studies have demonstrated that miRNA 
expression patterns are dysregulated in diverse human can-
cers, indicating that miRNAs plays important roles in the 
initiation and progression of cancers.6,7 In addition, miRNA 
expression profiles and specific miRNAs have been shown 
to be correlated with survival of a variety of human cancers, 
including lung cancer.8,9
Single nucleotide polymorphisms (SNPs) in pre-
miRNAs can alter miRNAs processing and expression, 
thereby contributing to cancer development and progression.10 
Recently, four potentially functional SNPs in pre-miRNAs 
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(pre-miR-146a rs2910164, pre-miR-149 rs2292832, pre-miR-
196a rs11614913, and pre-miR-499 rs3746444), which were 
selected among common SNPs located in pre-miRNAs and 
their surrounding regions of known human miRNAs listed in 
public database miRBase,11 have demonstrated that they do 
affect the susceptibility to a variety of human cancers.12–14 
Moreover, the pre-miR-196a rs11614913 has been reported 
to be associated with the prognosis of patients with NSCLC 
in Chinese populations.15 Therefore, to further verify the 
impact of these four SNPs in pre-miRNAs on the prognosis 
of lung cancer, we evaluated the association of the four SNPs 
on survival outcomes of patients with surgically resected 
NSCLC.
PATIENTS AND METHODS
Patients
This study included patients (n = 363) with stage I, II, 
or IIIA (microinvasive N2) NSCLC who underwent cura-
tive surgical resection at the Kyungpook National University 
Hospital, Daegu, Korea between September 1998 and 
December 2007, and whose tumor tissues were available for 
DNA. The clinicopathologic characteristics of the patients 
are shown in Table 1. All the patients included were native 
Koreans, and only those patients who had not received che-
motherapy or radiotherapy before surgery were included, so 
as to avoid the effects on DNA. Written informed consent was 
obtained from all patients before surgery, and this study was 
approved by the institutional review board of the Kyungpook 
National University Hospital. The pathologic staging of the 
tumors was determined according to the International System 
for Staging Lung Cancer.3
Genotyping
The four SNPs were genotyped using a polymerase 
chain reaction (PCR)-restriction fragment length polymor-
phism assay. The primer sequences and annealing tempera-
ture for the PCR analysis and the restriction enzymes for the 
rs2910164, rs2292832, rs11614913, and rs3746444 genotypes 
are shown in Supplementary Table 1 (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A406). Genotyping 
analysis was performed blind with respect to the case/control 
status to ensure quality control. Approximately 10% of the 
samples were randomly selected to be genotyped again by a 
different investigator, and the results were found to be 100% 
concordant.
Quantitative Reverse Transcription-PCR
Quantitative reverse transcription-PCR was performed 
to determine the expression of miR-149 according to the 
rs2292832T>C genotypes. RNAs from NSCLC tissues and 
paired nonmalignant lung tissues (n = 42; genotype distri-
bution: 23 TT, 16 TC, and 3 CC) were isolated using Trizol 
(Invitrogen, Carlsbad, CA). Expression levels of mature and 
primary form of miR-149 were determined using TaqMan 
MicroRNA Assays (Applied Biosystems, Foster City, CA). 
The small nuclear RNA U6 and glyceraldehyde 3-phosphate 
dehydrogenase were used to normalize the expression of 
mature and primary miRNAs, respectively. All real-time PCR 
was performed in triplicate using a LightCycler 480 (Roche 
Applied Science, Mannheim, Germany) according to manu-
facturer’s protocol. Relative expression was calculated using 
the C
t
 values provided by the manufacturer.
Statistical Analysis
Differences in the distribution of genotypes according to 
clinicopathologic factors of the patients were compared using2 
tests. The Hardy–Weinberg equilibrium was tested by com-
paring the observed and expected genotype frequencies using 
a goodness-of-fit2 test. The primary outcomes used for the 
present study were overall survival (OS) and disease-free sur-
vival (DFS). OS was measured from the day of surgery until 
the date of death or the date of the last follow-up. DFS was 
calculated from the day of surgery until recurrence or death 
from any cause. The survival estimates were calculated using 
the Kaplan–Meier method. The differences in OS and DFS 
across different genotypes were compared using the log-rank 
test. Hazard ratios (HRs) and 95% confidence intervals (CIs) 
were estimated using multivariate Cox proportional hazards 
models, with adjustment for age (≤63 versus >63 years), sex 
(female versus male), smoking status (never smokers versus 
ever smokers), pathologic stage (I versus II–IIIA), and adju-
vant therapy (yes versus no). A homogeneity test was per-
formed to compare the difference between genotype-related 
HRs of the different groups. All analyses were performed 
using Statistical Analysis System for Windows, version 9.2 
(SAS Institute, Cary, NC).
RESULTS
The clinical and pathological characteristics of patients 
and their association with OS and DFS are shown in Table 1. 
There were 141 deaths (38.8%), and the estimated 5-year OS 
and DFS for all the patients was 54% (95% CI, 48%–60%) 
and 44% (95% CI, 37%–50%), respectively. The pathological 
stage was significantly associated with OS and DFS (log-rank 
p [p
L-R
] < 0.0001, both). There was no significant difference 
in survival outcomes by age, sex, smoking status, histologic 
subtype, or adjuvant therapy.
The genotype frequencies of the four SNPs were in 
Hardy–Weinberg equilibrium. None of the four SNPs were 
significantly associated with patient- or tumor-related factors, 
such as age, sex, smoking status, or histologic subtype, 
except for the genotype distribution of the rs2910164, which 
differed significantly according to sex and smoking status 
(Supplementary Table 2, Supplemental Digital Content 
1, http://links.lww.com/JTO/A406). Of the four SNPs 
examined, the pre-miR-149 rs2292832T>C and pre-miR-
196a rs11614913C>T were significantly associated with 
OS and DFS (Table 2; Fig. 1; and Supplementary Table 
3, Supplemental Digital Content 1, http://links.lww.com/
JTO/A406). The rs2292832 TC or CC genotype exhibited a 
significantly better OS and DFS compared with the rs2292832 
TT genotype (adjusted HR [aHR] for OS, 0.66; 95% CI, 0.47–
0.92; p = 0.01 and aHR for DFS, 0.64; 95% CI, 0.48–0.87; p 
= 0.004). For the pre-miR-196a rs11614913C>T, patients with 
the CT or TT genotype had a significantly better OS and DFS 
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than those with the CC genotype (aHR for OS, 0.70; 95% CI, 
0.49–0.99; p = 0.05 and aHR for DFS, 0.66; 95% CI, 0.48–
0.90; p = 0.01).
The association of the rs2292832T>C and 
rs11614913C>T SNPs with survival outcomes was further 
examined after categorizing the patients by age, sex, smok-
ing status, histology, pathologic stage, and adjuvant therapy 
(Table 3). The effects of the two SNPs on OS and DFS were 
not significantly affected by clinicopathologic factors (p value 
of test for homogeneity [p
H
] > 0.05 for all comparisons).
We next examined the combined effects of the two 
SNPs (rs2292832T>C and rs11614913C>T) on the survival 
outcomes of the patients. Because the rs2292832 TC or CC 
genotype and the rs11614913 CT or TT genotype were associ-
ated with better survival outcomes, we considered these geno-
types to be indicators of a good prognosis and evaluated their 
combined effects by grouping the patients on the number of 
the good genotypes each patient possessed. Compared with 
the reference group of patients with zero good genotypes, OS 
and DFS improved in a dose-dependent manner as the num-
ber of good genotypes increased (p
trend
 = 0.002 and 0.0001, 
respectively). In multivariate analysis, patients with two good 
genotypes had a significantly better OS and DFS compared 
with those with 0 good genotypes (aHRs for OS, 0.46; 95% 
CI, 0.28–0.74; p = 0.002 and aHRs for DFS, 0.42; 95% CI, 
0.27–0.66; p = 0.0001; Table 4; Fig. 1C).
To characterize the functional relevance of the pre-
miR-149 rs2292832T>C, we evaluated the relationship 
between the rs2292832T>C genotypes and the expression of 
primary and mature forms of miR-149 in all the 42 cases. As 
shown in Figure 2, the levels of primary and mature miR-149 
expression were significantly higher in tumor tissues than in 
nonmalignant lung tissues (p = 0.02 and p = 0.01, respec-
tively). However, there was no significant difference of mature 
miR-149 expression levels in the rs2292832T>C genotypes in 
both nonmalignant lung tissues and tumor tissues.
DISCUSSION
Several studies have identified many significant genetic 
associations for lung cancer, the replication of which has 
often failed in independent studies.16,17 In the present study, 
we determined the association between pre-miRNA SNPs 
TABLE 1.  Univariate Analysis for OS and DFS by Age, Sex, Smoking Status, Histological Type, Pathologic Stage, and Adjuvant 
Therapy
Variables No. of Cases
OS DFS
No. of Death (%)a 5-Yr OSR (%)b Log-Rank p No. of Event (%)a 5-Yr DFSR (%)b Log-Rank P
Overall 363 141 (38.8) 54 181 (49.9) 44
Age, yr
 ≤63 185 66 (35.7) 59 0.07 90 (48.7) 46 0.39
 >63 178 75 (42.1) 49 91 (51.1) 41
Sex
 Women 85 24 (28.2) 61 40 (47.1) 44 0.84
 Men 278 117 (42.1) 53 0.14 141 (50.7) 43
Smoking status
 Never 82 25 (30.5) 62 0.27 41 (50.0) 40 0.56
 Ever 281 116 (41.3) 52 140 (49.8) 44
Pack-yearsc
 <40 127 49 (38.6) 55 0.25 62 (48.8) 45 0.75
 ≥40 154 67 (43.5) 51 78 (50.7) 44
Histological type
 Squamous cell carcinoma 202 75 (37.1) 57 0.65 93 (46.0) 47 0.15
 Adenocarcinoma 155 63 (40.7) 49 85 (54.8) 37
 Large-cell carcinoma 6 3 (50.0) 67 3 (50.0) 67
Pathologic stage
 I 220 58 (26.4) 65 <0.0001 79 (35.9) 55 <0.0001
 II 58 33 (56.9) 44 41 (70.7) 32
 IIIA 85 50 (58.8) 38 61 (71.8) 23
Adjuvant therapyd
 No 79 42 (53.2) 41 0.81 54 (68.4) 30 0.88
 Yes 64 41 (64.1) 39 48 (75.0) 24
a Row percentage.
b 5-year OSR and 5-year DFSR, proportion of survival derived from Kaplan–Meier analysis.
c In ever smokers.
d In pathologic stage II+IIIA: 59 cases received paclitaxel–cisplatin, two cases received radiotherapy, and three cases received chemotherapy and radiotherapy.
OSR, overall survival rate; DFSR, disease-free survival rate.
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and the prognosis of NSCLC in a Chinese population15 and 
replicated it in a Korean population. Among the four SNPs, 
rs2292832T>C and rs11614913C>T were significantly 
associated with a better OS and DFS in patients with early-
stage NSCLC, under a dominant model for the minor allele of 
each SNP. This finding was in agreement with the results of the 
previous Chinese study,15 in which the associations between 
the four pre-miRNA SNPs and the OS of 663 NSCLC patients 
(test set, n = 556; and validation set, n = 107) that consisted of 
167 stage I disease (25.2%), 83 stage II disease (12.5%), 260 
stage III disease (39.2%), and 153 stage IV disease (23.1%) 
were evaluated. In the Chinese study, similar to the results of 
our study, two SNPs (rs2292832T>C and rs11614913C>T) 
were associated with OS of the patients, but the other two 
FIGURE. 1.  Overall survival and disease-free survival curves according to genotypes: (A) pre-miR-149 rs2292832 TC or CC vs. 
TT genotype; (B) pre-miR-196a rs11614913 CT or TT vs. CC genotype, and (C) the combined genotypes of the two polymor-
phisms (1 and 2 good genotypes vs. none of good genotypes). p values in the multivariate Cox hazard models.
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SNPs (rs2910164C>G and rs3746444A>G) were not. 
Moreover, in the Chinese study, the rs2292832 TC or CC and 
rs11614913 CT or TT genotypes were associated with a higher 
OS compared with the rs2292832 TT and rs11614913 CC 
genotypes, respectively. The similar direction of associations 
in a similar genetic model across two studies from different 
ethnic populations provides strong evidence that the pre-
miR-149 rs2292832T>C and pre-miR-196a rs11614913C>T 
may affect malignant phenotypes of NSCLC.
In the present study, the pre-miR-196a rs11614913 CT 
or TT genotype was associated with better survival outcomes. 
This finding is biologically plausible. Recently, miRNA 
profiling studies have shown that miR-196a is up-regulated 
in human cancers, including NSCLC.18 Emerging evidence 
indicates that miR-196a plays an oncogenic role in the 
pathogenesis of human cancers, such as cell proliferation, 
migration, and invasion through targeting several genes, 
including homeobox B7 (HOXB7), HOXC8, HOXA5, and 
annexin A1.19–22 In addition, it has been reported that the 
rs11614913 CC genotype was associated with an increased 
expression of mature miR-196a.15 Therefore, it is reasonable 
that lung cancer patients with the rs11614913 CT or TT have a 
decreased level of mature miR-196a expression, which would 
result in a better survival outcome.
The biological mechanism of the observed associa-
tion between the pre-miR-149 rs2292832T>C and survival 
outcomes of patients with early-stage NSCLC is currently 
unknown. To determine whether the rs2292832T>C alters 
mature miR-149 expression, we compared the levels of 
mature miR-149 expression according to the rs2292832T>C 
TABLE 3.  Stratified Analysis of the Effects of the rs2292832 and rs11614913 Genotypes under a Dominant Model for the 
Minor Allele at each Polymorphism on Survival Outcomes by Selected Variables
 
SNP/Variables
Overall Survival Disease-Free Survival
Adjusted HR (95% CI)a pa p H Adjusted HR (95% CI)a pa p
 
H
rs2292832
 Age, yr
  ≤63 0.61 (0.37–1.02) 0.06 0.89 0.69 (0.45–1.06) 0.09 0.44
  >63 0.64 (0.40–1.03) 0.06 0.54 (0.34–0.84) 0.01
 Sex
  Male 0.76 (0.53–1.10) 0.15 0.09 0.71 (0.50–0.99) 0.05 0.31
  Female 0.32 (0.13–0.82) 0.02 0.48 (0.24–0.95) 0.04
 Smoking
  Never 0.46 (0.20–1.06) 0.07 0.34 0.64 (0.33–1.23) 0.18 0.97
  Ever 0.72 (0.50–1.04) 0.08 0.65 (0.46–0.92) 0.01
 Histological type
  SCC 0.70 (0.45–1.11) 0.13 0.50 0.61 (0.41–0.93) 0.02 1.00
  AC 0.55 (0.32–0.93) 0.03 0.61 (0.38–0.96) 0.03
 Pathologic stage
  I 0.72 (0.43–1.22) 0.22 0.80 0.70 (0.45–1.10) 0.13 0.73
  II+IIIA 0.66 (0.42–1.02) 0.06 0.63 (0.42–0.94) 0.03
rs11614913
 Age, yr
  ≤63 0.60 (0.36–1.01) 0.06 0.41 0.52 (0.34–0.81) 0.004 0.12
  >63 0.81 (0.49–1.33) 0.40 0.86 (0.54–1.36) 0.52
 Sex
  Male 0.78 (0.53–1.16) 0.23 0.10 0.72 (0.50–1.04) 0.08 0.34
  Female 0.34 (0.13–0.85) 0.02 0.49 (0.24–0.98) 0.04
 Smoking
  Never 0.44 (0.18–1.08) 0.07 0.30 0.61 (0.30–1.22) 0.16 0.84
  Ever 0.74 (0.50–1.10) 0.14 0.66 (0.46–0.94) 0.02
 Histological type
  SCC 0.67 (0.41–1.10) 0.11 0.66 0.55 (0.35–0.84) 0.01 0.12
  AC 0.79 (0.46–1.34) 0.38 0.92 (0.57–1.49) 0.72
 Pathologic stage
  I 0.88 (0.49–1.57) 0.66 0.27 0.81 (0.50–1.32) 0.40 0.29
  II+IIIA 0.58 (0.37–0.92) 0.02 0.57 (0.37–0.87) 0.01
a HR, 95% CIs, and corresponding p values were calculated using multivariate Cox proportional hazard models, adjusted for other variables.
SNP, single nucleotide polymorphism; HR, hazards ratio; CI, confidence interval; SCC, squamous cell carcinoma; AC, adenocarcinoma; p
H
, p value of test for homogeneity.
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genotypes and found no significant difference in mature miR-
149 expression levels by the genotypes in both NSCLC tissues 
and nonmalignant lung tissues. Recently, it has been reported 
that miR-149 induces apoptosis by repressing v-akt murine 
thymoma viral oncogene homolog 1 (AKT1) and E2F tran-
scription factor 1 (E2F1) expression in human cancer cells.23 
Considering that the AKT signaling cascade and E2F1 are 
aberrantly activated in lung cancer,24 it is possible that the 
pre-miR-149 2292832T>C modulates expression of target 
gene mRNAs, including AKT1 and E2F1 mRNAs, by alter-
ing target binding of miR-149, thereby contributing to survival 
outcomes. However, this hypothesis must be verified in future 
studies.
Emerging evidences suggest that the miRNA expression 
profile is different according to tumor histology.18,25 In 
addition, the effect of SNPs in pre-miRNAs on prognosis 
may be dependent on the pathologic stage of the disease. 
Therefore, stratification analysis was performed to determine 
whether the pre-miRNA SNPs might have differential 
effects on survival outcomes of the patients according to 
clinicopathologic characteristics of patients, including tumor 
histology and pathologic stage. In the stratification analyses, 
the rs2292832 genotypes were significantly associated with 
OS and DFS in women and adenocarcinoma, but not in men 
and squamous cell carcinomas. In addition, the rs11614913 
genotypes were significantly associated with OS and DFS 
in women and stage II+IIIA, but not in men and stage I. 
However, the differences in genotype-related aHRs between 
the different subgroups were not statistically significant 
(p
H
 > 0.05 for all comparisons). Therefore, further study with 
a larger sample size is needed to clarify whether these SNPs 
may have differential effects on survival outcomes according 
to clinicopathologic features.
In the present study, the rs2910164C>G and 
rs3746444A>G were not significantly associated with survival 
outcomes. This finding is consistent with a previous study 
that these two SNPs were not related to survival outcomes of 
Chinese patients with NSCLC.15 These results suggest that the 
TABLE 4.  Combined Effects of the rs2292832 and rs11614913 Genotypes on Survival Outcomes of Patients with  
Non–Small-Cell Lung Cancer
 
No. of Good 
Genotype
 
 
rs2292832
 
 
rs11614913
 
No. of  
Casesa,b
Overall Survival Disease-Free Survival
No. of  
Death (%)c
HR  
(95% CI)d
 
pd
No. of  
Event (%)c
HR  
(95% CI)d
 
pd
0 TT CC 52 (14.7) 27 (51.9) 1.00 32 (61.5) 1.00
1 TT CT+TT 117 (33.1) 50 (42.7) 0.68 (0.42–1.10) 0.11 63 (53.9) 0.69 (0.44–1.06) 0.09
1 TC+CC CC 53 (15.0) 20 (37.7) 0.62 (0.34–1.12) 0.11 27 (50.9) 0.66 (0.39–1.11) 0.12
2 TC+CC CT+TT 132 (37.3) 42 (31.8) 0.46 (0.28–0.74) 0.002 54 (40.9) 0.42 (0.27–0.66) 0.0001
p
trend
0.002 0.0001
0 52 (14.7) 27 (51.9) 1.00 32 (61.5) 1.00
1 170 (48.0) 70 (41.2) 0.66 (0.42–1.05) 0.08 90 (50.9) 0.68 (0.45–1.03) 0.07
2 132 (37.3) 42 (31.8) 0.46 (0.28–0.74) 0.002 54 (40.9) 0.42 (0.27–0.66) 0.0001
p
trend
0.002 0.0001
a Nine patients with missing genotype data at any of the rs2292832 and rs11614913.
b Column percentage.
c Row percentage.
d HRs, 95% CIs, and corresponding p values were calculated using multivariate Cox proportional hazard models, adjusted for age, sex, smoking status, tumor histology, pathologic 
stage, and adjuvant therapy.
HRs, hazard ratios; CIs, confidence intervals.
FIGURE. 2.  Effect of the 
rs2292832T>C genotypes on miR-
149 expression. Glyceraldehyde 
3-phosphate dehydrogenase and the 
small nuclear RNA U6 were used to 
normalize the expression of primary 
and mature miR-149, respectively. 
(A) Expression levels of primary 
and mature miR-149 in tumors and 
normal lung tissues. Expression levels 
of primary and mature forms of miR-
149 by the rs2292832T>C genotypes 
in normal lung tissues (B) and tumor 
tissues (C). Data represent median 
and quartiles. *p = 0.02, **p = 0.01.
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miR-146a and miR-499 may not play an important role in deter-
mining the prognosis of NSCLC, or that the rs2910164C>G 
and rs3746444A>G may not be functional SNPs. However, the 
ethnic variation in genetic variants warrants additional study to 
clarify the association of these two SNPs with the prognosis of 
patients with early-stage NSCLC in diverse ethnic populations.
We replicated the reported association of the pre-
miR-149 rs2292832T>C and pre-miR-196a rs11614913C>T 
with survival outcomes of patients with NSCLC, providing 
credible evidence that these genetic variants influence the 
prognosis of lung cancer. However, because genomic variation 
is greater when compared across populations of different 
ancestries, the challenge remains to extend the studies to 
Caucasian and African populations. In addition, future study 
on the biological function of the pre-miR-149 rs2292832T>C 
is needed to understand the role of the miR-149 in determining 
the prognosis of lung cancer.
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